The promise and challenges of bioengineered recombinant clotting factors
- 1 August 2005
- journal article
- review article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 3 (8), 1692-1701
- https://doi.org/10.1111/j.1538-7836.2005.01367.x
Abstract
No abstract availableKeywords
This publication has 83 references indexed in Scilit:
- Enhanced factor VIII activity measurements using ROTEG and factor VIII-/- mice whole bloodJournal of Thrombosis and Haemostasis, 2004
- New high‐technology products for the treatment of haemophiliaHaemophilia, 2004
- Clinical Gene Transfer Studies for Hemophilia BSeminars in Thrombosis and Hemostasis, 2004
- Coagulation Factors with Improved Properties for Hemophilia Gene TherapySeminars in Thrombosis and Hemostasis, 2004
- Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigationJournal of Thrombosis and Haemostasis, 2004
- The future of recombinant coagulation factorsJournal of Thrombosis and Haemostasis, 2003
- Use of recombinant factor IX in subjects with haemophilia B undergoing surgeryHaemophilia, 2002
- Use of Recombinant Antihemophilic Factor in the Treatment of Two Patients with Classic HemophiliaNew England Journal of Medicine, 1989
- Molecular cloning of a cDNA encoding human antihaemophilic factorNature, 1984
- Characterization of the human factor VIII geneNature, 1984